Anemia Management News

Akebia Therapeutic’ s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor showed positive results in the first of two global phase 3 cardiovascular outcomes programs when compared to darbepoetin alfa for the treatment of anemia in patients on dialysis, company officials said.

Heart failure hospitalizations and eGFR decline are associated with anemic patients with chronic kidney disease, according to an abstract from the virtual National Kidney Foundation Spring Clinical Meetings.

No clinically relevant changes were found with vadadustat pharmacokinetic exposure following co-administration of rabeprazole and vadadustat, according to a speaker at the virtual National Kidney Foundation Spring Clinical Meetings.

In clinical trials, patients with nondialysis-dependent chronic kidney disease using the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat saw an increase in hemoglobin levels regardless of their iron status, according to an abstract presented at the virtual National Kidney Foundation Spring Clinical Meetings.

Use of the oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat helped reduce the need for red blood cell transfusions compared to placebo in patients with chronic kidney disease not on dialysis, studies show.

On February 12, the FDA accepted its first new drug application for a hypoxia-inducible factor prolyl hydroxylase inhibitor. The agency has set a Prescription Drug User Fee Act date of Dec. 20, 2020 for final review and approval.

The FDA has accepted a new drug application for roxadustat, a drug already approved for the treatment of chronic kidney disease-related anemia in China, according to a press release from FibroGen Inc. The NDA applies to both nondialysis dependent CKD (NDD-CKD) patients and patients on dialysis.

KANSAS CITY, Mo. — Erythropoietin stimulating agent use can be reduced with improved nutrition and increased use of vitamin D in patients on hemodialysis, according to results of a study presented at The Annual Dialysis Conference.

The FDA approved ferric derisomaltose injection for the treatment of iron deficiency anemia in adults who had an intolerance or unsatisfactory response to oral iron or who have nonhemodialysis-dependent chronic kidney disease, according to a press release from the drug’s manufacturer.

WASHINGTON — Survey results presented at ASN Kidney Week indicated that most patients with chronic kidney disease-related anemia experienced physical symptoms and decreased emotional well-being, but their understanding of the condition varied.